Expanded Access To Pembrolizumab from Cost-Savings Generated by Biosimilar Filgrastim (BIOSIM-FIL) in The Prophylaxis of Chemotherapy-Induced (FEBRILE) Neutropenia (CIN/FN)- Simulation Study
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.258
https://www.valueinhealthjournal.com/article/S1098-3015(17)30592-2/fulltext
Title :
Expanded Access To Pembrolizumab from Cost-Savings Generated by Biosimilar Filgrastim (BIOSIM-FIL) in The Prophylaxis of Chemotherapy-Induced (FEBRILE) Neutropenia (CIN/FN)- Simulation Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30592-2&doi=10.1016/j.jval.2017.08.258
First page :
A443
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
237